A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
A phase 3 trial testing SCTC21C in multiple myeloma, now recruiting.
Overview
A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant is a phase 3 interventional study registered as NCT07297329, led by Sinocelltech, and recruiting when checked on 2026-09-11. Official title: A Phase 3 Randomised, Open-label, Multicenter Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Lenalidomide and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant. Planned enrolment is 292 participants (estimated). The study started in 2025-12-29 and primary completion is expected in 2027-12. No results have been posted on ClinicalTrials.gov.
Similar pages
not linked directly; found by shared links- TrialA Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Shares Sinocelltech and the tag ctgov-ingest.
- TrialA Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma
Shares Sinocelltech and the tag ctgov-ingest.
- TrialA Study to Evaluate the Safety and Tolerability of SCTB14 as First-Line Therapy in Non-Small Cell Lung Cancer
Shares Sinocelltech and the tag ctgov-ingest.
- TrialSCTB41 Combined With Chemotherapy in Advanced Squamous Non-Small Cell Lung Cancer
Shares Sinocelltech and the tag ctgov-ingest.
- TrialA Study of GR1803 Injection Versus Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Participants With Relapsed or Refractory Multiple Myeloma
Shares Multiple myeloma and the tag ctgov-ingest.
- TrialA Multicenter, Randomized, Open-label, Parallel-group, Controlled, Superiority Phase III Clinical Study Comparing the Efficacy and Safety of F182112 Versus Standard of Care in Patients With Relapsed or Refractory Multiple Myeloma
Shares Multiple myeloma and the tag ctgov-ingest.
- TrialA Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
Shares Multiple myeloma and the tag ctgov-ingest.
- TrialA Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
Shares Multiple myeloma and the tag ctgov-ingest.